Clinical Pharmacology, Division Director - Clinical Pharmacology & Toxicology ChildrenS Me.... Job in Kansas City Gr8Jobs
Children's Mercy Hospital (MO)
Kansas City, MO (In Person)
Full-Time
Skill Insights
Compare your current skills to what this opportunity needs—we'll show you what you already have and what could strengthen your application.
Job Description
Job Description The Department of Pediatrics at Childrens Mercy seeks a creative and scholarly leader to serve as Division Director of Clinical Pharmacology, Toxicology, and Therapeutic Innovation. The Division Director will be responsible for leading the research, educational, and quality missions of Clinical Pharmacology, an academic division focused on providing clinical consultation and research programs aimed at making the use of medications in children safer and more effective. Within the division, the Section of Medical Toxicology provides consultative services for potential poison exposures, including overdoses, environmental exposures, and envenomations. The Division Director will foster collaborative ties throughout Childrens Mercy, bridging the divisions research missions in genomic, clinical research, and translational interests across the Department of Pediatrics and CMRI. This is a faculty position offering academic appointments at the University of Missouri Kansas City School of Medicine and the Kansas University School of Medicine, rank to be commensurate with experience. Kansas City's strong culture of philanthropy has led to the creation of many endowed roles available to distinguished and accomplished leaders. An endowed position may be extended to the selected candidate, contingent upon their qualifications and record of achievement. Established in 1996, Clinical Pharmacology has a national and international reputation for impactful translational science and excellence in training. The Division has a strong record for successful extramural funding and an outstanding publication record. Clinical Pharmacology faculty and staff are national leaders in pharmacogenetics, institutional leaders in health equity research, and outstanding clinicians, using pharmacology and toxicology to improve the care of patients. Among the groups in the Division are: GOLDILOKs Clinic (GOLDILOKS stands for Genomic- and OntogenyLinked Dose Individualization and cLinical Optimization for KidS.) is a multidisciplinary clinic with a pediatrician, clinical pharmacist, and nurse who see patients with a variety of conditions including adverse drug reactions, drug-drug interactions, and medication nonresponse. Additionally, the clinical staff meet weekly with genetics lab experts and a social worker to discuss upcoming patients and formulate a multidisciplinary care plan individualized to each patient. The clinic offers educational opportunities to pharmacy students, medical students, residents, and fellows. The Medical Toxicology Consult Team provides consultative services for a variety of environmental, exposure, overdose and poison issues. A Children's Mercy Medical Toxicologist is on call 24 hours a day, seven days a week. Our toxicologists also provide medical direction for the Kansas Poison Control Center. This service on average has 150-200 beside consults per year. Academically, the toxicologists provide lectures to CMH Pediatric Emergency Medicine fellows and residents, CMH Pediatric Medicine fellows, TMC/University Health Emergency Medicine residents, and 5th/6th year UMKC medical students. In continuing the collaboration of research, Kansas Fights Addiction Grant-Opioid Withdrawal Treatment Clinical Practice Guideline was rewarded. Childrens Mercy Hospital (CMH) Pediatric Clinical Pharmacology (T32) training program is the Division of Clinical Pharmacology and Toxicology at CMH one of the largest and most comprehensive Pediatric Clinical Pharmacology programs in North America. Our fellowship training program is accredited by the American Board of Clinical Pharmacology (ABCP) and has formally trained 31 fellows since 1998 (21 pediatricians, 6 pharmacists, 1 advanced practice nurse, 3 PhD scientists). The drug biotransformation core serves to characterize drug disposition pathways along with the consequences of drug metabolizing enzyme (DME) polymorphisms in subcellular systems derived from pediatric tissues. A cell culture facility permits fellows and faculty to explore the regulation and expression of DME related proteins. A robust analytical core supports in vitro and in vivo pharmacology- and metabolomics-related research, emphasizing the characterization of developmental trajectories of drug disposition and response pathways. Partnerships with University of Kansas Nuclear Magnetic Resonance (NMR) spectroscopy core allow for the characterization of drug metabolites or biomarker development. The Analytical Chemistry Core Director can provide both didactic and hands-on instruction to our trainees on quantitative pharmacology methods. We have an internationally recognized pharmacogenetics/genomics (PGx) program defining gene sequence variations related to drug disposition and action. This program also administers the Pharmacogene Variation (PharmVar) Consortium. The Pharmacogene Variation (PharmVar) Consortium is a globally recognized central repository for pharmacogene (PGx) variation. The major focus of PharmVar is to catalogue allelic variation of genes impacting drug metabolism, disposition and response and provide a unifying designation system (nomenclature) for the global pharmacogenetic/genomic community. A team of dedicated health care providers and researchers in our Clinical Pharmacology Division and Division of Clinical Genetics and Genomics offer an in-house pharmacogenetic test called Kiddose PGx. This test helps clinicians better understand how to dose medications for each specific patient when genetic differences may play a role in their bodys response to pharmaceuticals. Quality Improvement projects include Decreasing Turnaround Time of Pharmacogenetic Testing which won a poster award at the UMKC School of Medicine QIPS Day. Currently, there is an ongoing project to Decrease Insurance Preauthorization Time for Pharmacogenetic Testing. Within our faculty roster, we have someone who is an UMKC School of Medicine QIPS Faculty Scholar. Through strategic team science collaboration with colleagues locally, nationally and internationally, Clinical Pharmacology, Toxicology, and Therapeutic Innovation has leveraged Childrens Mercy strengths in clinical care, genomics, and clinical pharmacology to improve care, enhance research and speed translation of best practice into the community. The foremost qualities necessary for this position is vision for the field of clinical pharmacology research and patient care. Other desired characteristics include 1) a track record of extramural funding; 2) history of mentorship that includes developing young investigators into independent scientists; 2) interest in academic infrastructure and research finances; 3) successful collaborations with administration, hospital, medical, and research partners; 4) unwavering commitment to the principles of diversity, equity and inclusion; and 5) commitment to developing a culture of high team accountability and professionalism. The individual selected for this position will be a strategic and highly communicative leader with a doctoral degree (MD, DO, MD/PhD, DO/PhD, PhD, or PharmD). The Division Director of Clinical Pharmacology, Toxicology & Therapeutic Innovation reports to the Chair of Pediatrics. About Childrens Mercy Childrens Mercy is one of the United States leading non-profit, independent pediatric health systems, offering a comprehensive suite of departments, centers, and clinics. Founded in 1897, Childrens Mercy is dedicated to holistic care, impactful research, breakthrough innovation and educating the next generation of caregivers. Guided by our mission, vision and values, our aim is to create a world of wellbeing for all children. Childrens Mercy is consistently ranked among the best childrens hospitals in the nation by US News & World Report, and we were the first hospital in Missouri or Kansas to receive Magnet designation for excellence in patient care from the American Nurses Credentialing Center an honor we have received five consecutive times. Some Childrens Mercy facts and figures: 390 licensed beds Nearly 800 faculty Over 50 specialties 600,000 total visits 190,000 emergency and urgent care visits 20,000 surgical cases Primary service area includes150 counties in Missouri and Kansas Level 1 Childrens Surgery Center by the American College of Surgeons Only pediatric Level 1 Trauma Center between St. Louis and Denver Comprehensive solid organ transplant center with sustained, exceptional outcomes Education Education is a core tenet of Childrens Mercy. Childrens Mercy provides education opportunities to nursing students, medical students, residents and fellows, supporting over 1,400 learners annually. Childrens Mercy is the pediatric clerkship site for both UMKC and KU medical students and provides elective rotations and sub-internships to students at any accredited allopathic or osteopathic medical school. Childrens Mercy is highly active in Graduate Medical Education with accredited residencies in pediatrics, med/peds, child neurology, pediatric dentistry, pediatric optometry and pharmacy. Childrens Mercy offers more than 40 fellowship programs across numerous areas, developing the next generation of subspecialists. Certificate and masters programs are also operated in conjunction with its academic partners, the University of Kansas (KU) and the University of Missouri Kansas City (UMKC). Finally . click apply for full job details